Literature DB >> 25777752

Mouse Models of Primary Sjogren's Syndrome.

Young-Seok Park, Adrienne E Gauna, Seunghee Cha1.   

Abstract

Sjogren's syndrome (SjS) is a chronic autoimmune disorder characterized by immune cell infiltration and progressive injury to the salivary and lacrimal glands. As a consequence, patients with SjS develop xerostomia (dry mouth) and keratoconjunctivitis sicca (dry eyes). SjS is the third most common rheumatic autoimmune disorder, affecting 4 million Americans with over 90% of patients being female. Current diagnostic criteria for SjS frequently utilize histological examinations of minor salivary glands for immune cell foci, serology for autoantibodies, and dry eye evaluation by corneal or conjunctival staining. SjS can be classified as primary or secondary SjS, depending on whether it occurs alone or in association with other systemic rheumatic conditions, respectively. Clinical manifestations typically become apparent when the disease is relatively advanced in SjS patients, which poses a challenge for early diagnosis and treatment of SjS. Therefore, SjS mouse models, because of their close resemblance to the human SjS, have been extremely valuable to identify early disease markers and to investigate underlying biological and immunological dysregulations. However, it is important to bear in mind that no single mouse model has duplicated all aspects of SjS pathogenesis and clinical features, mainly due to the multifactorial etiology of SjS that includes numerous susceptibility genes and environmental factors. As such, various mouse models have been developed in the field to try to recapitulate SjS. In this review, we focus on recent mouse models of primary SjS xerostomia and describe them under three categories of spontaneous, genetically engineered, and experimentally induced models. In addition, we discuss future perspectives highlighting pros and cons of utilizing mouse models and current demands for improved models.

Entities:  

Mesh:

Year:  2015        PMID: 25777752      PMCID: PMC4425610          DOI: 10.2174/1381612821666150316120024

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  180 in total

1.  Effects of oral consumption of the green tea polyphenol EGCG in a murine model for human Sjogren's syndrome, an autoimmune disease.

Authors:  Kevin Gillespie; Isamu Kodani; Douglas P Dickinson; Kalu U E Ogbureke; Amy M Camba; Mengjie Wu; Stephen Looney; Tin-Chun Chu; Haiyan Qin; Frederick Bisch; Mohamed Sharawy; George S Schuster; Stephen D Hsu
Journal:  Life Sci       Date:  2008-09-06       Impact factor: 5.037

2.  Immunization with 60 kD Ro peptide produces different stages of preclinical autoimmunity in a Sjögren's syndrome model among multiple strains of inbred mice.

Authors:  B T Kurien; A Dsouza; A Igoe; Y J Lee; J S Maier-Moore; T Gordon; M Jackson; R H Scofield
Journal:  Clin Exp Immunol       Date:  2013-07       Impact factor: 4.330

3.  Electron microscopic study of subcapsular cell hyperplasia in the adrenal glands of IQI/Jic mice.

Authors:  Jong-Soo Kim; Hisayo Kubota; Toshio Sakai; Kunio Doi; Junzo Saegusa
Journal:  Exp Anim       Date:  2005-01

4.  Autoimmune disease of exocrine organs in immunodeficient alymphoplasia mice: a spontaneous model for Sjögren's syndrome.

Authors:  R Tsubata; T Tsubata; H Hiai; R Shinkura; R Matsumura; T Sumida; S Miyawaki; H Ishida; S Kumagai; K Nakao; T Honjo
Journal:  Eur J Immunol       Date:  1996-11       Impact factor: 5.532

5.  Estrogen deficiency accelerates autoimmune exocrinopathy in murine Sjögren's syndrome through fas-mediated apoptosis.

Authors:  N Ishimaru; K Saegusa; K Yanagi; N Haneji; I Saito; Y Hayashi
Journal:  Am J Pathol       Date:  1999-07       Impact factor: 4.307

6.  Passive transfer of Sjogren's syndrome IgG produces the pathophysiology of overactive bladder.

Authors:  Fang Wang; Michael W Jackson; Vicki Maughan; Dana Cavill; Anthony J Smith; Sally A Waterman; Tom P Gordon
Journal:  Arthritis Rheum       Date:  2004-11

Review 7.  Sjögren's syndrome.

Authors:  Robert I Fox
Journal:  Lancet       Date:  2005 Jul 23-29       Impact factor: 79.321

8.  A rapamycin-binding protein polymer nanoparticle shows potent therapeutic activity in suppressing autoimmune dacryoadenitis in a mouse model of Sjögren's syndrome.

Authors:  Mihir Shah; Maria C Edman; Srikanth R Janga; Pu Shi; Jugal Dhandhukia; Siyu Liu; Stan G Louie; Kathleen Rodgers; J Andrew Mackay; Sarah F Hamm-Alvarez
Journal:  J Control Release       Date:  2013-07-25       Impact factor: 9.776

9.  Autoimmunity against a tissue kallikrein in IQI/Jic Mice: a model for Sjogren's syndrome.

Authors:  Kensuke Takada; Mitsuyoshi Takiguchi; Akihiro Konno; Mutsumi Inaba
Journal:  J Biol Chem       Date:  2004-11-15       Impact factor: 5.157

10.  Pathogenic effect of interleukin-17A in induction of Sjögren's syndrome-like disease using adenovirus-mediated gene transfer.

Authors:  Cuong Q Nguyen; Hongen Yin; Byung Ha Lee; Wendy C Carcamo; John A Chiorini; Ammon B Peck
Journal:  Arthritis Res Ther       Date:  2010-12-23       Impact factor: 5.156

View more
  40 in total

Review 1.  Lacrimal gland development: From signaling interactions to regenerative medicine.

Authors:  Ankur Garg; Xin Zhang
Journal:  Dev Dyn       Date:  2017-08-18       Impact factor: 3.780

Review 2.  What can Sjögren's syndrome-like disease in mice contribute to human Sjögren's syndrome?

Authors:  Ammon B Peck; Cuong Q Nguyen
Journal:  Clin Immunol       Date:  2017-05-03       Impact factor: 3.969

3.  Pathogenesis-based treatments in primary Sjogren's syndrome using artificial intelligence and advanced machine learning techniques: a systematic literature review.

Authors:  Nathan Foulquier; Pascal Redou; Christophe Le Gal; Bénédicte Rouvière; Jacques-Olivier Pers; Alain Saraux
Journal:  Hum Vaccin Immunother       Date:  2018-06-28       Impact factor: 3.452

4.  The Sustained Effects on Tear Volume of Pilocarpine Hydrochloride in Gelatin by Hydrogel Administered by An Implant-mediated Drug Delivery System.

Authors:  Seunghee Cha; Hong-Kyun Kim; Hong-Seop Kho; Young-Seok Park
Journal:  Curr Drug Deliv       Date:  2017       Impact factor: 2.565

Review 5.  The NZB/W F1 mouse model for Sjögren's syndrome: A historical perspective and lessons learned.

Authors:  Harini Bagavant; Aleksandra Michrowska; Umesh S Deshmukh
Journal:  Autoimmun Rev       Date:  2020-10-22       Impact factor: 9.754

Review 6.  Studying Sjögren's syndrome in mice: What is the best available model?

Authors:  Ghada Abughanam; Ola M Maria; Simon D Tran
Journal:  J Oral Biol Craniofac Res       Date:  2020-12-08

7.  Impaired GATE16-mediated exocytosis in exocrine tissues causes Sjögren's syndrome-like exocrinopathy.

Authors:  Akiko Suzuki; Chihiro Iwaya; Kenichi Ogata; Hiroki Yoshioka; Junbo Shim; Isei Tanida; Masaaki Komatsu; Norihiro Tada; Junichi Iwata
Journal:  Cell Mol Life Sci       Date:  2022-05-20       Impact factor: 9.261

Review 8.  Intracrine Regulation of Estrogen and Other Sex Steroid Levels in Endometrium and Non-gynecological Tissues; Pathology, Physiology, and Drug Discovery.

Authors:  Gonda Konings; Linda Brentjens; Bert Delvoux; Tero Linnanen; Karlijn Cornel; Pasi Koskimies; Marlies Bongers; Roy Kruitwagen; Sofia Xanthoulea; Andrea Romano
Journal:  Front Pharmacol       Date:  2018-09-19       Impact factor: 5.810

9.  NOD and NOR mice exhibit comparable development of lacrimal gland secretory dysfunction but NOD mice have more severe autoimmune dacryoadenitis.

Authors:  Yaping Ju; Srikanth Reddy Janga; Wannita Klinngam; J Andrew MacKay; Dillon Hawley; Driss Zoukhri; Maria C Edman; Sarah F Hamm-Alvarez
Journal:  Exp Eye Res       Date:  2018-09-08       Impact factor: 3.467

Review 10.  Myeloid-derived suppressor cells as cellular immunotherapy in transplantation and autoimmune diseases.

Authors:  Jilu Zhang; Alan Hodges; Shu-Hsia Chen; Ping-Ying Pan
Journal:  Cell Immunol       Date:  2021-02-04       Impact factor: 4.868

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.